Editas Medicine, Inc. (EDIT)

Over the past six months, Editas Medicine's stock price has declined by 26.62%. Key events include the release of third quarter 2025 results and business updates, presentations of EDIT-401 preclinical data, a narrower-than-expected Q3 loss and an increase in year-over-year revenues, and an increase in the price target by Fintel. The stock performance has been described as "pretty rough across the board".

Editas Medicine's progress is influenced by clinical trial results, regulatory milestones, strategic collaborations, and investor sentiment rather than traditional consumer demand seasonality.

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines using CRISPR gene editing technology. The company is developing EDIT-101, a CRISPR-based gene therapy for Leber congenital amaurosis type 10 (LCA10). EDIT-301 is an experimental treatment for severe hematologic diseases. EDIT-401 is designed to reduce LDL cholesterol levels, with plans for clinical trials. Editas Medicine collaborates with other companies for oncology and other liver targets.

Editas Medicine's primary operations are in the United States, with headquarters in Cambridge, Massachusetts, and facilities in Boulder, Colorado. Its global reach extends through clinical trials and collaborations.

Editas Medicine is recognized as a pioneer in gene editing with expertise in CRISPR technology. However, the company's reputation has faced challenges due to a workforce reduction, management turnover, negative market sentiment, and financial performance issues.

Editas Medicine has a mixed ownership structure including institutional, insider, and retail investors. Institutional investors own approximately 15.99% to 44.12% of the company's stock. Insiders own approximately 0.55% to 33.76% of the stock. Retail investors hold approximately 22.12% to 71.79% of the company's stock.